Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
450 participants
INTERVENTIONAL
2005-06-30
2009-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Escitalopram
10 to 20 mg / day
2
Placebo
1-2 capsules
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Escitalopram
10 to 20 mg / day
Placebo
1-2 capsules
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. The patient has signed the Patient Informed Consent.
3. The patient has sufficient knowledge of Hebrew in order to understand the study procedure and instruments
4. The patient is male or female aged between 18 and 65 years (extremes included).
5. The patient underwent a traumatic event, such as vehicle or other accident, terror attack, physical or sexual assault within the last 3 weeks, and no more than 4 weeks ago.
6. The patient meets either of the following criteria:
1\. Full DSM-IV criteria for ASD 2. Intrusion and hyperarousal criteria only
Exclusion Criteria
2. The patient has a serious physical injury at inclusion, in which his Abbreviated Injury Scale (AIS) score, for at least one of his body regions, is 3 or more, or that according to the judgment of the clinician his injury sequelae would interfere with the study treatment.
3. The patient uses concomitant medications not allowed in the study:
1. Antidepressants, including MAOI, RIMA within the last 3 weeks prior to screening.
2. Mood stabilizers within the last 3 weeks prior to screening.
3. Antipsychotic medications within the last 3 weeks prior to screening.
4. Anxiolytics 2 weeks in a row before randomization. Patient can participate in the study if did not take the medications for 3 days over the two weeks before randomization. Except for oxazepam 10-20 mg/day no more than 7 days in a raw.
5. Serotonergic agonists (e.g. triptans) within the last 2 weeks prior to screening.
6. Prophylactic treatment with any anticonvulsant drug.
7. Herbal remedies that are psychoactive (e.g. St John's Wort, Kava kava, valerian, gingko biloba) within the last 3 weeks prior to screening.
4. The patient meets lifetime DSM-IV-TR criteria for:
1. Mania or Bipolar disorder
2. Schizophrenia
3. Any personality disorder judged by the investigator to jeopardize the evaluation of the treatment.
4. Mental retardation or pervasive disorder
5. Cognitive disorder (inc. dementia)
5. The patient has or has had alcohol or drug abuse related disorders in the last year prior to the screening visit.
6. The patient has, in the investigator's opinion, significant suicide risk and/or a score of ≥ 5 on question 10 in the MADRS scale.
7. The patient has a history of severe suicide attempt.
8. The patient requires ElectroConvulsive Therapy (ECT) or has received ECT within the last year prior to the screening visit.
9. The patient is currently serving in the Israeli security forces.
10. The patient has a history of drug allergy or hypersensitivity, or known hypersensitivity to escitalopram or citalopram.
11. The patient has an illness and/or serious sequelae thereof, severe enough according to the clinician judgment, to prevent his participation in the study, including liver or renal insufficiency; cardiovascular, pulmonary, gastrointestinal, endocrine (inc. uncontrolled thyroid), neurological (inc. epilepsy), infectious, neoplastic, or metabolic disturbances
12. The patient is pregnant or breast-feeding.
13. The patient, if woman of childbearing potential, is not using adequate contraception (adequate contraception is defined as sexual abstinence, oral/systemic contraception, surgical sterilisation, intrauterine device, diaphragm in combination with spermicide, or condom for male partner in combination with spermicide).
14. The patient, in the opinion of the investigator, is unlikely to comply with the clinical study protocol.
15. The patient has previously participated in the current study or in any other study within the last 30 days.
16. The patient has familial relationships with the investigator.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sheba Medical Center
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Prof. Joseph Zohar
Prof. Joseph Zohar
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Joseph Zohar, MD
Role: STUDY_DIRECTOR
Chaim Sheba Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Barzilai Medical Center
Ashkelon, , Israel
Soroka Medical Center
Beersheba, , Israel
RAMBAM Medical Center
Haifa, , Israel
Hadassa Medical Center
Jerusalem, , Israel
Chaim Sheba Medical Center
Ramat Gan, , Israel
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Bertolini F, Robertson L, Bisson JI, Meader N, Churchill R, Ostuzzi G, Stein DJ, Williams T, Barbui C. Early pharmacological interventions for prevention of post-traumatic stress disorder (PTSD) in individuals experiencing acute traumatic stress symptoms. Cochrane Database Syst Rev. 2024 May 20;5(5):CD013613. doi: 10.1002/14651858.CD013613.pub2.
Bertolini F, Robertson L, Bisson JI, Meader N, Churchill R, Ostuzzi G, Stein DJ, Williams T, Barbui C. Early pharmacological interventions for universal prevention of post-traumatic stress disorder (PTSD). Cochrane Database Syst Rev. 2022 Feb 10;2(2):CD013443. doi: 10.1002/14651858.CD013443.pub2.
Zohar J, Fostick L, Juven-Wetzler A, Kaplan Z, Shalev H, Schreiber G, Miroshnik N, Shalev AY, Stein DJ, Seedat S, Suliman S, Klein E. Secondary Prevention of Chronic PTSD by Early and Short-Term Administration of Escitalopram: A Prospective Randomized, Placebo-Controlled, Double-Blind Trial. J Clin Psychiatry. 2018 Mar/Apr;79(2):16m10730. doi: 10.4088/JCP.16m10730.
Suliman S, Seedat S, Pingo J, Sutherland T, Zohar J, Stein DJ. Escitalopram in the prevention of posttraumatic stress disorder: a pilot randomized controlled trial. BMC Psychiatry. 2015 Feb 19;15:24. doi: 10.1186/s12888-015-0391-3.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SHEBA-06-3913-JZ-CTIL
Identifier Type: -
Identifier Source: org_study_id